Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Aredia (pamidronate)
- Gavreto (pralsetinib)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
pralsetinib food
Applies to: Gavreto (pralsetinib)
Food should not be consumed for at least 2 hours before and at least 1 hour after taking pralsetinib. Do not consume grapefruit, grapefruit juice, any supplements that contain grapefruit, Seville oranges, or Seville orange juice as these products can increase the blood levels of pralsetinib. This may increase the risk and/or severity of serious side effects such as lung problems, liver problems, high blood pressure, fatigue, muscle and joint pain, and bleeding complications. Some sources also warn that combining these medicines could increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac disease, conduction abnormalities, or electrolyte disturbance (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Prolia
Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every ...
Reclast
Reclast (zoledronic acid) is used to treat osteoporosis in women after menopause and also to treat ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Zometa
Zometa is used to treat high blood levels of calcium caused by cancer and multiple myeloma. Learn ...
Xgeva
Xgeva prevents bone fractures and other skeletal conditions in people with multiple myeloma, and is ...
Wyost
Wyost (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) by a ...
Jubbonti
Jubbonti (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) once ...
Aclasta
Aclasta (zoledronic acid) inhibits the release of calcium from bones and is used to treat Paget's ...
Zoledronic acid
Zoledronic acid is used for hypercalcemia of malignancy, osteolytic bone lesions of multiple ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.